These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 28814833)

  • 1. Markers of oxidative/nitrosative stress and inflammation in lung tissue of rats exposed to different intravenous iron compounds.
    Toblli JE; Cao G; Giani JF; Dominici FP; Angerosa M
    Drug Des Devel Ther; 2017; 11():2251-2263. PubMed ID: 28814833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The complex interplay of iron metabolism, reactive oxygen species, and reactive nitrogen species: insights into the potential of various iron therapies to induce oxidative and nitrosative stress.
    Koskenkorva-Frank TS; Weiss G; Koppenol WH; Burckhardt S
    Free Radic Biol Med; 2013 Dec; 65():1174-1194. PubMed ID: 24036104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nitrosative Stress and Apoptosis by Intravenous Ferumoxytol, Iron Isomaltoside 1000, Iron Dextran, Iron Sucrose, and Ferric Carboxymaltose in a Nonclinical Model.
    Toblli JE; Cao G; Giani JF; Dominici FP; Angerosa M
    Drug Res (Stuttg); 2015 Jul; 65(7):354-60. PubMed ID: 25050519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous iron sucrose reverses anemia-induced cardiac remodeling, prevents myocardial fibrosis, and improves cardiac function by attenuating oxidative/nitrosative stress and inflammation.
    Toblli JE; Cao G; Rivas C; Giani JF; Dominici FP
    Int J Cardiol; 2016 Jun; 212():84-91. PubMed ID: 27038710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of toxicity and oxidative stress induced by intravenous iron isomaltoside 1000 in a nonclinical model.
    Toblli JE; Cao G; Oliveri L; Angerosa M
    Arzneimittelforschung; 2011; 61(10):553-65. PubMed ID: 22164963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the extent of oxidative stress induced by intravenous ferumoxytol, ferric carboxymaltose, iron sucrose and iron dextran in a nonclinical model.
    Toblli JE; Cao G; Oliveri L; Angerosa M
    Arzneimittelforschung; 2011; 61(7):399-410. PubMed ID: 21899208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences between original intravenous iron sucrose and iron sucrose similar preparations.
    Toblli JE; Cao G; Oliveri L; Angerosa M
    Arzneimittelforschung; 2009; 59(4):176-90. PubMed ID: 19517894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physico-chemical properties of the new generation IV iron preparations ferumoxytol, iron isomaltoside 1000 and ferric carboxymaltose.
    Neiser S; Rentsch D; Dippon U; Kappler A; Weidler PG; Göttlicher J; Steininger R; Wilhelm M; Braitsch M; Funk F; Philipp E; Burckhardt S
    Biometals; 2015 Aug; 28(4):615-35. PubMed ID: 25801756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ferrous sulfate, but not iron polymaltose complex, aggravates local and systemic inflammation and oxidative stress in dextran sodium sulfate-induced colitis in rats.
    Toblli JE; Cao G; Angerosa M
    Drug Des Devel Ther; 2015; 9():2585-97. PubMed ID: 26005335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron supplementation at high altitudes induces inflammation and oxidative injury to lung tissues in rats.
    Salama SA; Omar HA; Maghrabi IA; AlSaeed MS; EL-Tarras AE
    Toxicol Appl Pharmacol; 2014 Jan; 274(1):1-6. PubMed ID: 24215938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular, liver, and renal toxicity associated with an intravenous ferric carboxymaltose similar versus the originator compound.
    Toblli JE; Cao G; Rico L; Angerosa M
    Drug Des Devel Ther; 2017; 11():3401-3412. PubMed ID: 29238166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of iron dextran on the oxidative stress in cardiovascular tissues of rats with chronic renal failure.
    Lim CS; Vaziri ND
    Kidney Int; 2004 May; 65(5):1802-9. PubMed ID: 15086920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Induction of Oxidative/Nitrosative Stress, Inflammation, and Apoptosis by a Ferric Carboxymaltose Copy Compared to Iron Sucrose in a Non-Clinical Model.
    Toblli JE; Cao G; Angerosa M
    J Clin Diagn Res; 2015 Dec; 9(12):FF08-12. PubMed ID: 26816915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sinapic acid mitigates gentamicin-induced nephrotoxicity and associated oxidative/nitrosative stress, apoptosis, and inflammation in rats.
    Ansari MA; Raish M; Ahmad A; Ahmad SF; Mudassar S; Mohsin K; Shakeel F; Korashy HM; Bakheet SA
    Life Sci; 2016 Nov; 165():1-8. PubMed ID: 27664833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients.
    Prats M; Font R; García C; Muñoz-Cortés M; Cabré C; Jariod M; Romeu M; Giralt M; Martinez-Vea A
    Clin Nephrol; 2014 Jun; 81(6):419-26. PubMed ID: 24691014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute and sub-acute effect of ferric carboxymaltose on inflammation and adhesion molecules in patients with predialysis chronic renal failure.
    Prats M; Font R; García-Ruiz C; Cabré C; Muñoz-Cortés M; Nogués MR; Jariod M; Romeu M; Martínez-Vea A
    Nefrologia; 2013; 33(3):355-61. PubMed ID: 23640119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iron and oxidative stress in renal insufficiency.
    Lim CS; Vaziri ND
    Am J Nephrol; 2004; 24(6):569-75. PubMed ID: 15550752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term exposure to crotonaldehyde causes heart and kidney dysfunction through induction of inflammatory and oxidative damage in male Wistar rats.
    Zhang B; Li S; Men J; Peng C; Shao H; Zhang Z
    Toxicol Mech Methods; 2019 May; 29(4):263-275. PubMed ID: 30426860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of iron deficiency anemia and its treatment with iron polymaltose complex in pregnant rats, their fetuses and placentas: oxidative stress markers and pregnancy outcome.
    Toblli JE; Cao G; Oliveri L; Angerosa M
    Placenta; 2012 Feb; 33(2):81-7. PubMed ID: 22153683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parenteral iron compounds: potent oxidants but mainstays of anemia management in chronic renal disease.
    Zager RA
    Clin J Am Soc Nephrol; 2006 Sep; 1 Suppl 1():S24-31. PubMed ID: 17699373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.